Antifibrinolytic agents: aprotinin, and desmopressin.
作者信息
Bajaj Pramila
机构信息
Editor, IJA.
出版信息
Indian J Anaesth. 2009 Jun;53(3):268-9.
Abstract
摘要
相似文献
1
Antifibrinolytic agents: aprotinin, and desmopressin.抗纤溶药物：抑肽酶和去氨加压素。
Indian J Anaesth. 2009 Jun;53(3):268-9.
2
Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: a meta-analysis.抗纤溶药物对脊柱手术中手术出血和输血需求的疗效：一项荟萃分析。
Eur Spine J. 2017 Jan;26(1):140-154. doi: 10.1007/s00586-016-4792-x. Epub 2016 Sep 26.
3
Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study.
J Thorac Cardiovasc Surg. 1995 Oct;110(4 Pt 1):1107-17. doi: 10.1016/s0022-5223(05)80180-1.
4
Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery.
Ann Pharmacother. 2001 Sep;35(9):1075-84. doi: 10.1177/106002800103500905.
5
CU-2010--a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties.CU - 2010——一种具有抗纤维蛋白溶解和抗凝特性的新型小分子蛋白酶抑制剂。
Anesthesiology. 2009 Jan;110(1):123-30. doi: 10.1097/ALN.0b013e318191408c.
6
The safety and efficacy of antifibrinolytic therapy in neonatal cardiac surgery.抗纤溶疗法在新生儿心脏手术中的安全性和有效性。
PLoS One. 2015 May 8;10(5):e0126514. doi: 10.1371/journal.pone.0126514. eCollection 2015.
7
[Transfusion requirements, morbidity and mortality in cardiac surgery and the use of antifibrinolytic agents: a comparison of aprotinin and tranexamic acid].[心脏手术中的输血需求、发病率和死亡率以及抗纤溶药物的使用：抑肽酶和氨甲环酸的比较]
Rev Esp Anestesiol Reanim. 2011 Mar;58(3):140-6. doi: 10.1016/s0034-9356(11)70020-2.
8
Effects of antifibrinolytic agents on the life span of fibrin sealant.抗纤溶药物对纤维蛋白密封剂寿命的影响。
J Surg Res. 1992 Oct;53(4):402-7. doi: 10.1016/0022-4804(92)90068-b.
9
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.减少心脏手术中过度失血的药理学策略：对临床相关终点的荟萃分析
Lancet. 1999 Dec 4;354(9194):1940-7. doi: 10.1016/S0140-6736(99)01264-7.
10
The use of haemostatic drugs in haemophilia: desmopressin and antifibrinolytic agents.
Haemophilia. 2002 May;8(3):189-93. doi: 10.1046/j.1365-2516.2002.00645.x.
本文引用的文献
1
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?抗纤溶药物能否减少骨科手术中的异体输血？
Anesthesiology. 2006 Nov;105(5):1034-46. doi: 10.1097/00000542-200611000-00026.
2
Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes.冠状动脉搭桥手术中全剂量抑肽酶的应用：围手术期药物治疗及患者预后分析
Anesth Analg. 2006 Nov;103(5):1082-8. doi: 10.1213/01.ane.0000238447.74029.f5.
3
Aprotinin use in thoracic aortic surgery: safety and outcomes.
J Thorac Cardiovasc Surg. 2006 Oct;132(4):909-17. doi: 10.1016/j.jtcvs.2006.06.021.
4
Treatment of von Willebrand's Disease.血管性血友病的治疗
N Engl J Med. 2004 Aug 12;351(7):683-94. doi: 10.1056/NEJMra040403.
5
Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study.抑肽酶与安慰剂用于大型骨科手术的对照研究：一项随机、双盲、剂量范围研究
Anesth Analg. 2002 Aug;95(2):287-93, table of contents. doi: 10.1097/00000539-200208000-00005.
6
The antithrombotic and antiinflammatory mechanisms of action of aprotinin.
Ann Thorac Surg. 2001 Dec;72(6):2169-75. doi: 10.1016/s0003-4975(01)02821-1.
7
Aprotinin and the systemic inflammatory response after cardiopulmonary bypass.抑肽酶与体外循环后的全身炎症反应
Ann Thorac Surg. 2001 Feb;71(2):745-54. doi: 10.1016/s0003-4975(00)02218-9.
8
Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group.
Lancet. 2000 Apr 15;355(9212):1303-9. doi: 10.1016/s0140-6736(00)02111-5.
9
Hemostatic drugs.止血药物。
N Engl J Med. 1998 Jul 23;339(4):245-53. doi: 10.1056/NEJM199807233390407.
10
The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification.
Anesthesiology. 1992 Jul;77(1):38-46. doi: 10.1097/00000542-199207000-00007.
Zotero 插件